Cumberland Pharmaceuticals Inc.
CPIXHealthcare|Drug Manufacturers - Specialty & Generic|US
$5.22
+0.21 (+4.19%)
Tangible Book / Share
$1.14
Cash / Share
$0.26
Financials
Financial Snapshot
Market Cap
$78.2M
Enterprise Value
$79.1M
Revenue (TTM)
$31.3M
Net Income (TTM)
-$10.6M
Cash & Investments
$3.9M
Net Cash
-$851.8K
Free Cash Flow (TTM)
-$1.1M
Operating CF (TTM)
$746.0K
Debt/Equity
0.27
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $50.1M | $50.1M | $36.2M | $28.2M | $24.8M | $27.0M | $19.8M | $18.3M | $18.0M | $11.4M | $3.9M | |
| Operating Cash Flow | $569.5K | -$557.7K | $3.1M | $3.1M | $5.4M | $6.3M | $8.5M | $6.1M | -$612.2K | $4.9M | $746.0K | |
| Free Cash Flow | -$1.6M | -$2.0M | -$1.2M | $2.8M | $3.3M | $6.0M | $6.4M | $5.6M | -$791.9K | $4.8M | -$1.1M | |
| Capital Expenditure | -$2.1M | -$1.5M | -$4.3M | -$246.2K | -$2.1M | -$354.5K | -$2.1M | -$453.1K | -$179.7K | -$97.9K | -$1.9M | |
| Financing Cash Flow | -$1.1M | $1.9M | $7.1M | -$5.1M | -$7.1M | -$3.6M | -$2.1M | -$7.4M | $196.9K | -$6.7M | -$7.2M |
R&D Spending
R&D (TTM)
$5.0M
R&D Intensity
16.1%
R&D Growth vs Prior
-9.6%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33.0M | $41.2M | $40.7M | $34.4M | $37.4M | $36.0M | $42.0M | $39.6M | $37.9M | $44.5M | $31.3M | |
| R&D Expense | $3.2M | $3.9M | $7.3M | $6.9M | $5.8M | $5.7M | $6.7M | $5.8M | $4.8M | $5.6M | $5.0M | |
| R&D % of Revenue | 9.7% | 9.5% | 18.0% | 20.0% | 15.4% | 15.8% | 15.9% | 14.8% | 12.7% | 12.5% | 16.1% | |
| SG&A | $23.1M | $31.5M | $30.7M | $25.3M | $25.0M | $24.8M | $26.8M | $29.1M | $28.1M | $31.0M | $27.4M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33.0M | $41.2M | $40.7M | $34.4M | $37.4M | $36.0M | $42.0M | $39.6M | $37.9M | $44.5M | $31.3M | |
| Cost of Revenue | $6.0M | $7.4M | $7.4M | $7.4M | $8.7M | $8.8M | $9.1M | $6.1M | $6.6M | $6.7M | $5.2M | |
| Gross Profit | $27.1M | $33.8M | $33.4M | $27.0M | $28.8M | $27.2M | $32.9M | $33.5M | $31.3M | $37.9M | $26.1M | |
| R&D | $3.2M | $3.9M | $7.3M | $6.9M | $5.8M | $5.7M | $6.7M | $5.8M | $4.8M | $5.6M | $5.0M | |
| SG&A | $23.1M | $31.5M | $30.7M | $25.3M | $25.0M | $24.8M | $26.8M | $29.1M | $28.1M | $31.0M | $27.4M | |
| Operating Income | -$1.4M | -$4.1M | -$7.4M | -$9.3M | -$6.4M | -$7.7M | -$5.7M | -$9.6M | -$6.4M | -$2.8M | -$9.6M | |
| Interest Expense | $106.4K | $92.9K | $195.8K | $246.2K | $263.6K | $98.0K | $586.0K | $667.9K | $605.5K | $496.0K | $309.2K | |
| Pretax Income | -$1.3M | -$3.9M | -$7.0M | -$9.3M | -$6.6M | -$5.6M | -$5.6M | -$6.3M | -$6.5M | -$2.8M | -$9.6M | |
| Net Income | -$944.7K | -$8.0M | -$7.0M | -$3.5M | -$3.3M | -$3.5M | -$5.6M | -$6.3M | -$6.5M | -$2.8M | -$10.6M | |
| EPS (Diluted) | -0.06 | -0.50 | -0.45 | -0.23 | -0.22 | -0.24 | -0.38 | -0.44 | -0.46 | -0.19 | -0.71 | |
| EBITDA | $1.2M | -$1.1M | -$8.2M | -$4.6M | -$1.6M | -$857.8K | $332.9K | $153.3K | $182.4K | $3.0M | -$5.1M | |
| Shares Out. (M) | 16.24 | 15.91 | 15.61 | 15.40 | 15.16 | 14.90 | 14.56 | 14.30 | 14.06 | 14.96 | 14.98 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34.5M | $45.4M | $27.9M | $28.2M | $24.8M | $27.0M | $19.8M | $18.3M | $18.0M | $11.4M | $3.9M | |
| Short-Term Investments | $15.6M | $4.7M | $8.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $65.5M | $68.7M | $74.9M | $50.2M | $50.0M | $45.7M | $45.9M | $35.7M | $36.5M | $37.1M | $33.6M | |
| Total Assets | $93.4M | $93.2M | $112.7M | $104.5M | $96.5M | $84.5M | $92.9M | $81.8M | $75.6M | $76.8M | $62.9M | |
| Total Current Liabilities | $14.8M | $17.7M | $27.8M | $24.2M | $25.7M | $19.3M | $28.6M | $28.0M | $31.6M | $36.7M | $35.2M | |
| Long-Term Debt | $4.1M | $9.8M | $20.0M | $18.5M | $15.0M | $15.0M | $16.2M | $12.8M | $10.2M | $5.2M | $0.00 | |
| Total Liabilities | $20.3M | $29.3M | $57.1M | $53.5M | $49.6M | $41.9M | $57.0M | $52.5M | $53.0M | $52.3M | $45.8M | |
| Stockholders' Equity | $73.2M | $64.1M | $55.8M | $51.1M | $47.0M | $42.8M | $36.3M | $29.6M | $22.9M | $24.9M | $17.4M | |
| Retained Earnings | $18.6M | $11.7M | $4.7M | $1.2M | -$2.1M | -$5.6M | -$11.2M | -$17.5M | -$24.0M | -$26.8M | -$34.4M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $569.5K | -$557.7K | $3.1M | $3.1M | $5.4M | $6.3M | $8.5M | $6.1M | -$612.2K | $4.9M | $746.0K | |
| Capital Expenditure | -$2.1M | -$1.5M | -$4.3M | -$246.2K | -$2.1M | -$354.5K | -$2.1M | -$453.1K | -$179.7K | -$97.9K | -$1.9M | |
| Free Cash Flow | -$1.6M | -$2.0M | -$1.2M | $2.8M | $3.3M | $6.0M | $6.4M | $5.6M | -$791.9K | $4.8M | -$1.1M | |
| Investing Cash Flow | -$3.1M | $9.5M | -$27.7M | $2.3M | -$1.8M | -$501.9K | -$13.7M | -$105.7K | $57.8K | -$4.7M | -$5.8M | |
| Financing Cash Flow | -$1.1M | $1.9M | $7.1M | -$5.1M | -$7.1M | -$3.6M | -$2.1M | -$7.4M | $196.9K | -$6.7M | -$7.2M | |
| Issuance of Stock | $0.00 | $0.00 | $200.9K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $5.3M | $5.3M | |
| Repurchase of Stock | -$2.5M | -$3.7M | -$2.9M | -$3.5M | -$1.9M | -$1.4M | -$1.1M | -$740.5K | -$579.0K | -$263.5K | -$71.4K | |
| Net Debt Issuance | $2.4M | $5.7M | $10.2M | -$1.5M | -$3.5M | $0.00 | $1.2M | -$3.4M | $2.5M | -$10.0M | -$5.2M | |
| Stock Based Comp. | $852.1K | $1.5M | $1.4M | $1.5M | $1.0M | $741.9K | $447.5K | $365.0K | $301.9K | $408.3K | $438.1K | |
| Net Change in Cash | -$3.7M | $10.9M | -$17.5M | $273.7K | -$3.5M | $2.3M | -$7.3M | -$1.4M | -$357.4K | -$6.5M | -$12.2M |
Dilution Tracker
Shares Outstanding
15M
5-Year Share Growth
-1.4%
Stock Issuance (TTM)
$5.3M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 16.24 | 15.91 | 15.61 | 15.40 | 15.16 | 14.90 | 14.56 | 14.30 | 14.06 | 14.96 | 14.98 | |
| Change vs Prior % | — | -2.0% | -1.9% | -1.4% | -1.5% | -1.7% | -2.3% | -1.8% | -1.7% | 6.4% | 0.2% | |
| Stock Issuance | $0.00 | $0.00 | $200.9K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $5.3M | $5.3M | |
| Stock Repurchase | -$2.5M | -$3.7M | -$2.9M | -$3.5M | -$1.9M | -$1.4M | -$1.1M | -$740.5K | -$579.0K | -$263.5K | -$71.4K | |
| Stock Based Comp. | $852.1K | $1.5M | $1.4M | $1.5M | $1.0M | $741.9K | $447.5K | $365.0K | $301.9K | $408.3K | $438.1K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 82.0% | 82.1% | 81.9% | 78.4% | 76.9% | 75.5% | 78.3% | 84.7% | 82.6% | 85.0% | 83.4% | |
| Operating Margin % | -4.3% | -9.9% | -18.1% | -27.0% | -17.0% | -21.3% | -13.6% | -24.2% | -17.0% | -6.3% | -30.8% | |
| Net Margin % | -2.9% | -19.4% | -17.1% | -10.3% | -8.9% | -9.7% | -13.3% | -15.9% | -17.1% | -6.4% | -33.9% | |
| EBITDA Margin % | 3.5% | -2.8% | -20.1% | -13.5% | -4.2% | -2.4% | 0.8% | 0.4% | 0.5% | 6.6% | -16.2% | |
| FCF Margin % | -4.7% | -5.0% | -2.9% | 8.2% | 8.8% | 16.6% | 15.2% | 14.3% | -2.1% | 10.9% | -3.6% | |
| ROE % | -1.3% | -12.4% | -12.5% | -6.9% | -7.1% | -8.2% | -15.4% | -21.2% | -28.4% | -11.4% | -47.1% | |
| ROA % | -1.0% | -8.6% | -6.2% | -3.4% | -3.5% | -4.2% | -6.0% | -7.7% | -8.6% | -3.7% | -16.9% | |
| ROIC % | -1.4% | -5.4% | -8.7% | -11.3% | -8.6% | -11.6% | -8.8% | -17.6% | -13.0% | -6.9% | -34.1% | |
| R&D / Revenue % | 9.7% | 9.5% | 18.0% | 20.0% | 15.4% | 15.8% | 15.9% | 14.8% | 12.7% | 12.5% | 16.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -1.5% | 24.6% | -1.0% | -15.6% | 8.9% | -3.9% | 16.7% | -5.9% | -4.3% | 17.6% | |
| Gross Profit | -5.2% | 24.8% | -1.2% | -19.2% | 6.8% | -5.6% | 21.0% | 1.8% | -6.6% | 21.0% | |
| Operating Income | -28.9% | -184.8% | -81.1% | -25.7% | 31.3% | -20.3% | 25.7% | -67.5% | 32.7% | 56.6% | |
| Net Income | -229.2% | -744.6% | 12.7% | 49.2% | 5.6% | -5.0% | -58.8% | -12.7% | -3.2% | 56.2% | |
| EPS (Diluted) | -245.5% | -759.1% | 10.0% | 48.9% | 4.3% | -9.1% | -58.3% | -15.8% | -4.5% | 58.7% | |
| Operating Cash Flow | -90.3% | -197.9% | 658.1% | -1.8% | 77.2% | 17.1% | 33.3% | -27.9% | -110.0% | 905.7% | |
| Free Cash Flow | -149.1% | -31.1% | 43.2% | 341.8% | 17.5% | 81.4% | 6.5% | -11.6% | -114.0% | 710.5% | |
| R&D Expense | -17.1% | 22.3% | 87.6% | -6.2% | -15.9% | -1.5% | 17.7% | -12.8% | -17.4% | 15.6% | |
| SG&A Expense | 7.0% | 36.4% | -2.7% | -17.6% | -1.1% | -0.7% | 8.2% | 8.4% | -3.3% | 10.3% | |
| Total Assets | 1.6% | -0.2% | 20.9% | -7.2% | -7.7% | -12.4% | 10.0% | -12.0% | -7.6% | 1.6% | |
| Book Value / Share | 1.1% | -13.5% | -11.2% | -7.0% | -6.8% | -7.5% | -13.6% | -17.2% | -21.6% | 2.3% | |
| Debt | 141.2% | 139.0% | 104.1% | 7.5% | -10.4% | -16.6% | 30.5% | -12.1% | 11.6% | -50.5% | |
| Diluted Shares | -5.0% | -2.0% | -1.9% | -1.4% | -1.5% | -1.7% | -2.3% | -1.8% | -1.7% | 6.4% |
Valuation
P/E (TTM)At Loss
P/S2.50
10Y Low / Med / High0.65 / 1.93 / 2.85
P/B4.48
10Y Low / Med / High0.86 / 1.55 / 2.39
EV/EBITDAAt Loss
10Y Low / Med / High19.70 / 102.03 / 196.97
EV/Revenue2.53
10Y Low / Med / High0.65 / 1.63 / 2.11
P/FCFAt Loss
10Y Low / Med / High4.54 / 12.31 / 28.22
Intrinsic Value Models (per share)
Tangible Book / Share
$1.14
Cash / Share
$0.26
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -91.67 | -14.72 | -13.40 | -22.39 | -13.41 | -19.46 | -5.92 | -4.07 | -5.15 | -20.95 | -7.31 | |
| P/S Ratio | 2.62 | 2.85 | 2.30 | 2.31 | 1.19 | 1.93 | 0.78 | 0.65 | 0.88 | 1.34 | 2.50 | |
| P/B Ratio | 1.18 | 1.83 | 1.68 | 1.55 | 0.95 | 1.63 | 0.90 | 0.86 | 1.46 | 2.39 | 4.48 | |
| EV/EBITDA | 48.09 | -71.85 | -10.50 | -15.64 | -25.19 | -68.34 | 102.03 | 167.64 | 196.97 | 19.70 | -15.58 | |
| EV/Revenue | 1.70 | 1.98 | 2.11 | 2.11 | 1.05 | 1.63 | 0.81 | 0.65 | 0.95 | 1.31 | 2.53 |
Analyst Estimates & Quality
Altman Z-Score
0.24
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $38.2M | $38.2M | $45.2M |
| Net Income | -$8.2M | -$8.2M | -$4.6M |
| EPS | $-0.55 | $-0.55 | $-0.31 |
| # Analysts (EPS) | 1 | 1 | 1 |
Dividends
Dividend/Share (TTM)
$1.50
Dividend Yield
28.74%
Frequency
Irregular
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Aug 3, 2026 | $1.50 | Irregular |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Acetadote | $1.9M | $851.0K | $501.0K | — | — | — |
| Caldolor | $5.3M | $5.0M | $4.8M | — | — | — |
| Kristalose | $15.6M | $16.0M | $15.2M | — | — | — |
| Omeclamox-Pak | $257.1K | -$388.7K | — | — | — | — |
| Product, Vibativ | $10.9M | $11.7M | $7.5M | — | — | — |
| RediTrex | $856.7K | $55.3K | -$126.7K | — | — | — |
| Vaprisol | $1.1M | $1.9M | -$447.7K | — | — | — |
| Sancuso | — | — | $13.2M | — | — | — |
| Manufactured Product, Other | — | — | — | $2.0M | $1.3M | — |
| Product | — | — | — | $37.5M | $36.5M | $40.4M |
| Product - Other | — | — | — | — | — | $4.1M |
| Product - Vibativ | — | — | — | — | — | $9.5M |
By Geography
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Non-US | $2.4M | $2.2M | $1.5M | $1.1M | $2.7M | $4.9M |